Previously, Cannabis Science has emphasized the importance of addressing the threat presented by Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Asthma is also an autoimmune disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

Dr. Melamede concluded by saying, We think that it is our duty to continue to emphasize that cannabis can play a very important role in treating respiratory diseases such as multiple influenza strains and asthma. There is an ever-increasing demand for our cannabis-based drugs, and this demand is growing exponentially throughout the United States and the rest of the world because it works. Modern science supports the public demand for cannabis-based FDA approved drug products that reduce the impact of critical life altering illnesses. The public need for our products drives our efforts to rapidly move our drugs through all available regulatory channels. We believe this enormous public demand on a global scale is a major key to our success and we are very excited to be positioned to provide solutions.

cannabisscience/